Penny Stocks
IMNN: ThermoDox Deal Gives a Written-Off Asset a New Path
IMUNON’s proposed ThermoDox sale offers contingent future value while management focuses on its Phase 3 ovarian-cancer program.
Read the storyTagged: Penny Stocks
STORIES WITH TASTE
Penny StocksKTTA: Pasithea Approaches Its October 23 Cancer-Data Presentation
An upcoming ESMO presentation gives Pasithea a defined clinical event as its shares rebound. The actual data will matter more than anticipation.
Penny StocksSHFS: Nasdaq Gives Safe Harbor More Time as Shares Rebound
A new compliance deadline gives Safe Harbor breathing room. Restoring its bid price and strengthening the business remain separate challenges.
Penny StocksNUAI: New Era’s AI Data-Center Plan Faces the Tenant Test
Power arrangements and credit support advance New Era’s infrastructure plan. Signed leases and project economics are the next commercial tests.
Penny StocksPDSB: A New Board as PDS Biotech Prepares Its Next Cancer-Trial Push
A board refresh gives PDS Biotechnology a timely business milestone. Clinical planning, financing and eventual patient evidence remain the investment tests.
Penny StocksDFSC: From Army Demonstrations to Commercial Orders—DEFSEC’s Next Test
DEFSEC’s corporate update puts product readiness and sales execution in focus. The key question is whether demonstrations and production become profitable customer orders.
Penny StocksXHLD: TEN Holdings Takes Its Digital-Experience Platform to Investors
Investor presentations put TEN Holdings’ strategy in the spotlight. Customer adoption, revenue quality and financial execution are the more durable tests.
Penny StocksESLA: Two Infusions, One Patient—and a Bigger Cancer-Therapy Question
Estrella’s recent EB103 update provides an early clinical milestone to examine. A small, short follow-up cannot establish broad safety or treatment benefit.
Penny StocksAMOD: Bitcoin Riches Meet the Per-Share Value Test
Alpha Modus highlights a larger digital-asset base. Investors must weigh that headline against the shares issued, conditional warrant proceeds and the separate retail-AI opportunity.
Penny StocksAHT: A $17 Million Fee Waiver Changes Ashford’s Liquidity Story
Ashford’s relief package puts liquidity and shareholder alignment in focus. The next test is whether that support improves the hotel owner’s financial position.
Penny StocksINVE: A $20 Million Tender Offer Puts a Price on Shareholder Returns
INVE’s tender offer gives investors a defined capital-return event to examine. The final purchase price, accepted shares and remaining business all matter.
Penny StocksOLOX: From Natural Gas to Computing Power—The Execution Test Begins
Olenox combines completed energy acquisitions with a Bitcoin production update. The opportunity depends on turning an expanding asset platform into reliable operating economics.